Literature DB >> 20493848

Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.

Noelia L Grosso1, Jacqueline Bua, Alina E Perrone, Mariela N Gonzalez, Patricia L Bustos, Miriam Postan, Laura E Fichera.   

Abstract

We describe some biological and molecular characteristics of a Trypanosoma cruzi isolate derived from a Triatomine captured in Nicaragua. PCR based typification showed that this isolate, named Nicaragua, belonged to the lineage Tc I. Nicaragua infected culture cells were treated with allopurinol, showing different behavior according to the cellular compartment, being cardiomyocyte primary cultures more resistant to this drug. The course of the infection in a mice experimental model and its susceptibility to benznidazole and allopurinol was analyzed. In benznidazole treatment, mice reverted the high lethal effect of parasites during the acute infection, however, a few parasites were detected in the heart of 88% of mice 1 year post-infection. Since T. cruzi is a heterogeneous species population it is important to study and characterize different parasites actually circulating in humans in endemic areas. In this work we show that T. cruzi Nicaragua isolate, is sensitive to early benznidazole treatment. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493848      PMCID: PMC2927352          DOI: 10.1016/j.exppara.2010.05.010

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  37 in total

1.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

2.  Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment.

Authors:  W Apt; A Arribada; I Zulantay; A Solari; G Sánchez; K Mundaca; X Coronado; J Rodríguez; L C Gil; A Osuna
Journal:  Ann Trop Med Parasitol       Date:  2005-12

3.  Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection.

Authors:  M Postan; J J Bailey; J A Dvorak; J P McDaniel; E W Pottala
Journal:  Am J Trop Med Hyg       Date:  1987-11       Impact factor: 2.345

4.  Molecular diagnosis and typing of Trypanosoma cruzi populations and lineages in cerebral Chagas disease in a patient with AIDS.

Authors:  Juan M Burgos; Sandra B Begher; Jorge M Freitas; Margarita Bisio; Tomas Duffy; Jaime Altcheh; Ricardo Teijeiro; Horacio Lopez Alcoba; Florencia Deccarlini; Hector Freilij; Mariano J Levin; Jorge Levalle; Andrea M Macedo; Alejandro G Schijman
Journal:  Am J Trop Med Hyg       Date:  2005-12       Impact factor: 2.345

5.  Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release.

Authors:  Laura Edith Fichera; Maria Cecilia Albareda; Susana Adriana Laucella; Miriam Postan
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  [Biological and genetic characterization of two Colombian clones of Trypanosoma cruzi groups I and II].

Authors:  Luz Adriana Botero; Ana Maria Mejía; Omar Triana
Journal:  Biomedica       Date:  2007-01       Impact factor: 0.935

7.  Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes.

Authors:  M J O Toledo; M T Bahia; V M Veloso; C M Carneiro; G L L Machado-Coelho; C F Alves; H R Martins; R E Cruz; W L Tafuri; M Lana
Journal:  J Antimicrob Chemother       Date:  2004-04-21       Impact factor: 5.790

8.  Molecular epidemiology of domestic and sylvatic Trypanosoma cruzi infection in rural northwestern Argentina.

Authors:  Marta V Cardinal; Marta A Lauricella; Leonardo A Ceballos; Leonardo Lanati; Paula L Marcet; Mariano J Levin; Uriel Kitron; Ricardo E Gürtler; Alejandro G Schijman
Journal:  Int J Parasitol       Date:  2008-05-24       Impact factor: 3.981

9.  Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.

Authors:  Edson L P Camandaroba; Eliana A G Reis; Marilda S Gonçalves; Mitermayer G Reis; Sonia G Andrade
Journal:  Rev Soc Bras Med Trop       Date:  2003-06-10       Impact factor: 1.581

10.  Short report: concurrent detection of Trypanosoma cruzi lineages I and II in domestic Triatoma dimidiata from Guatemala.

Authors:  Pamela M Pennington; Claudia Paiz; Laura M Grajeda; Celia Cordón-Rosales
Journal:  Am J Trop Med Hyg       Date:  2009-02       Impact factor: 2.345

View more
  4 in total

1.  Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.

Authors:  María L Scalise; Eva C Arrúa; Marcela S Rial; Mónica I Esteva; Claudio J Salomon; Laura E Fichera
Journal:  Am J Trop Med Hyg       Date:  2016-05-31       Impact factor: 2.345

2.  Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Authors:  Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

3.  Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism.

Authors:  Patricia Andrea Garavaglia; Marc Laverrière; Joaquín J B Cannata; Gabriela Andrea García
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.

Authors:  Marcela S Rial; María L Scalise; Eva C Arrúa; Mónica I Esteva; Claudio J Salomon; Laura E Fichera
Journal:  PLoS Negl Trop Dis       Date:  2017-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.